EUCTR2012-004295-19-DK
Active, not recruiting
Phase 1
A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. - EORTC protocol 1209-EnTF
European Organisation for Research and Treatment of Cancer (EORTC)0 sites142 target enrollmentFebruary 21, 2014
DrugsVargatef
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- European Organisation for Research and Treatment of Cancer (EORTC)
- Enrollment
- 142
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •? Histologically confirmed differentiated or medullary thyroid cancer by local pathologist.
- •? Available tumor tissue at the time of initial diagnosis for histology review.
- •? Locally advanced or metastatic disease deemed incurable by surgery, radiotherapy and/or radioactive iodine (RAI).
- •? Patients must have measurable lesion with documented progression during the 12 months prior to randomization.
- •? Patients must have received one or 2 prior line of treatment (but no more than two) and must be off treatment for at least 4 weeks prior to randomization. Patients with an MTC must have received one or 2 prior line of treatment (but no more than two) and must be off treatment for at least 4 weeks prior to randomization. If it is available and reimbursed in the respective country one of the prior lines of treatment needs to be with Vandetanib as long as there is no contraindication or the patient refuses the treatment with Vandetanib.
- •? Age \=18 years.
- •? Performance status (PS) 0\-1 (WHO, Appendix C).
- •? Life expectancy of more than 12 weeks.
- •? Adequate organ function, evidenced by the following laboratory results within 3 weeks prior to randomization
- •Are the trial subjects under 18? no
Exclusion Criteria
- •? Current symptomatic brain metastases or if previously present, must have been treated at least two months before randomization.
- •? History of other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin.
- •? Ongoing treatment related toxicity due to prior treatment \> grade I (except alopecia).
- •? History of significant cardiac disease
- •? Current uncontrolled hypertension
- •? Evidence of active bleeding or bleeding diathesis.
- •? Cerebrovascular accident at any time in the past, transient ischemic attack, deep venous thrombosis (DVT) or pulmonary embolism in the past 6 months
- •? History of clinically significant gastrointestinal disorders .
- •? Current severe, uncontrolled systemic disease or any other systemic disease/symptom that can hamper compliance with the protocol.
- •? Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.Histologically confirmed differentiated or medullary thyroid cancer by local pathologist.MedDRA version: 17.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-004295-19-FREuropean Organisation for Research and Treatment of Cancer. EORTC102
Active, not recruiting
Phase 1
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.EUCTR2012-004295-19-BEEuropean Organisation for Research and Treatment of Cancer (EORTC)102
Completed
Phase 2
A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with eitherc differentiated and medullary thyroid carcinoma progressing after first line therapy.thyroid cancerthyroid carcinoma10043739NL-OMON47685European Organisation for Research in Treatment of Cancer (EORTC)15
Active, not recruiting
Phase 1
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.Histologically confirmed differentiated or medullary thyroid cancer by local pathologist.MedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-004295-19-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)102
Active, not recruiting
Phase 1
A phase II study of second line therapy on safety and efficacy of nintedanib for patients with either differentiated or medullary thyroid cancer progressing after first line therapy.EUCTR2012-004295-19-ESEuropean Organisation for Research and Treatment of Cancer. EORTC102